Synthesis and Evaluation of Cytotoxic Activity of 3-((1H-Benzo[d]imidazol-2-yl)methyl)-2-phenylquinazolin-4(3H)-one Derivatives on MCF-7 Cell Line

Authors

  • Baljeet Singh Department of Pharmaceutical Sciences, Research Scholar, IKG Punjab Technical University, Kapurthala, Punjab, India
  • Shailesh Sharma Department of Pharmaceutical Sciences, ASBASJSM College of Pharmacy, Bela, Punjab, India.
  • Manish Sinha Department of AYUSH, Government Drug Testing Laboratory, Gwalior, Madhya Pradesh, India.
  • S. Saga Skanda Life Sciences Pvt Ltd., R and D center, Bengaluru, Karnataka, India.

DOI:

https://doi.org/10.21276/apjhs.2022.9.2.55

Keywords:

Breast cancer, Cytotoxic, MCF-7, Quinazolinone-4(3H)-one

Abstract

Cancers, particularly, breast cancer is one of the deadliest disease in women and requires to be treated with lowest side-effects and toxicity. Quinazolinone and Benzimidazole nucleus are privileged nucleus with reported anti-cancer activity. Hence, combined derivatives of 3-((1H-Benzo[d]imidazol-2-yl)methyl)-2-phenylquinazolin-4(3H)-one E(1-8) were prepared and tested for cytotoxicity on MCF-7 cell line. Compound E6 showed 70.74% inhibition of cell growth as compared to 86.96% inhibition by standard doxorubicin.

Downloads

Download data is not yet available.

Downloads

Published

2022-04-01

How to Cite

Baljeet Singh, Shailesh Sharma, Manish Sinha, & S. Saga. (2022). Synthesis and Evaluation of Cytotoxic Activity of 3-((1H-Benzo[d]imidazol-2-yl)methyl)-2-phenylquinazolin-4(3H)-one Derivatives on MCF-7 Cell Line. Asian Pacific Journal of Health Sciences, 9(2), 277–282. https://doi.org/10.21276/apjhs.2022.9.2.55

Issue

Vol. 9 No. 2 (2022): Vol 9 | Issue 2 | April - June 2022

Section

Articles

License

Copyright (c) 2022 Baljeet Singh, Shailesh Sharma, Manish Sinha, S. Saga

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Asian Pacific Journal of Health Sciences applies the Creative Commons Attribution (CC-BY) license to published articles. Under this license, authors retain ownership of the copyright for their content, but they allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. Appropriate attribution can be provided by simply citing the original article.